% Expired Patents = 75.0

EPO Patents = 2

Forward Citations = 1

Loading Chart...

3 inventors (with patents filed for the assignee):

Hans Dieplinger (3 out of 5 patents)

Florian Kronenberg (1 out of 5 patents)

Karl Oskar Illmensee (1 out of 1 patent)

4 patents: Sort by Forward Citations

1. 8129129 - Method for diagnosing tumors (2012-03-06),

2. 7842463 - Method of diagnosing early stage renal impairment (2010-11-30),

3. 7767406 - Method for diagnosing tumors (2010-08-03),

4. 6762033 - Method for determining the fertility of mammals, especially humans (2004-07-13),

Company Overview

Vitateq Biotechnology GmbH is a leading biotech company specializing in the development and production of innovative biopharmaceuticals. With a strong focus on research and development, we are committed to improving the quality of life for patients worldwide. Our cutting-edge technologies and scientific expertise drive our success in creating advanced treatments for various diseases.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

4 Patents

#16 in Innsbruck

#606 in Austria

Innsbruck, Austria

Vitateq Biotechnology Gmbh

Forward Citations = 1

3 inventors:

Hans Dieplinger (3 out of 5 patents)

Florian Kronenberg (1 out of 5 patents)

Karl Oskar Illmensee (1 out of 1 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Vitateq Biotechnology Gmbh. Retrieved from https://idiyas.com/company/vitateq-biotechnology

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

2 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]